Ono picks up Japan Relistor rights
This article was originally published in Scrip
Executive Summary
Onohas acquired exclusive Japanese rights to develop and commercialiseProgenics Pharmaceuticals' mu-opioid receptor antagonist Relistor (methylnaltrexone bromide), for $15 million up front and up to $20 million in development milestones. Ono will also pay sales-based royalties that analysts say could exceed the rate paid by Wyeth, Progenics' partner for Relistor outside Japan, and commercialisation milestones, which could be worth up to a further $20 million.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.